Colorectal cancer (CRC) is one of the most common malignant tumors of the digestive tract, and morbidity and mortality rank third and second in malignant tumors. [1][2][3] Currently, early screening for CRC can effectively improve the survival rate of patients with CRC, but approximately 25% of CRC patients develop metastatic disease from an early stage. [4][5][6] Therefore, a promising field of antimetastatic therapy lies in the targeted inhibition of cancer cells with high metastatic potential from the primary site. 7,8 Recently, there has been a qualitative leap in tumor medical technology, such as the application of laparoscopic surgery, nano-assembly technology, PET/ CT imaging technology, and dynamic network biomarker (DNB), etc. 9-11 However, the cure rate and survival rate of CRC are still very low, mainly lacking new drug treatment targets and biomarkers for the treatment of CRC. 12 According to the research of circular RNAs in the CRC field, circular RNAs are expected to be therapeutic targets